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Abstract
Methods: A total of 2426 study subjects from rural China aged 35 years and above (934 men and 1492 women)
were enrolled in a cross-sectional survey. The eGFR calculation was based on the Modification of Diet in Renal
Disease (MDRD) equation. The strength of the association between cardiovascular metabolic risk factors and eGFR
was analyzed using a linear regression model.
Results: Cardiovascular metabolic risk factors, including age, body weight, waist circumference, fasting plasma
glucose (FPG), creatinine (Cr), high-density lipoprotein-cholesterol (HDL-C), total cholesterol (TC), triglyceride (TG),
systolic pressure, and diastolic pressure, were associated with eGFR. Additionally, the eGFR level gradually decreased
and showed a linear trend with the increase in metabolic syndrome risk factors.
Conclusion: Metabolic risk factors are correlated with a reduction in renal function and CKD.
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Background
Chronic kidney disease (CKD) and cardiovascular
diseases severely threaten human health and life.
Compelling evidence shows that CKD and cardiovascu-
lar diseases usually occur together. These two diseases
have a common pathophysiological basis. Traditional
cardiovascular risk factors, including hypertension, hy-
peruricemia, advanced age, diabetes mellitus, increased
low-density lipoprotein-cholesterol (LDL-C), smoking,
and alcoholism, are also risk factors for kidney diseases
[1–5]. However, the association between cardiovascular
metabolic risk factors and CKD is uncertain for Chinese
individuals.
In addition, the aging of the population and economic
development have facilitated changes in the diet and
lifestyle of the Chinese population. Therefore, the preva-
lence of metabolic syndrome (MetS), which is primarily
characterized by obesity, hypertension, abnormal glucose
metabolism, blood lipid disorders, hyperinsulinemia, and
hyperuricemia, has gradually increased. Previous studies
showed that MetS was a common risk factor for cardio-
vascular diseases and CKD [6] and that some MetS
factors were associated with the development of CKD.
However, no previous study has investigated the
association between cardiovascular metabolic risk factors
and kidney function levels in a rural Chinese population.
Therefore, in the present study we examined the associ-
ation between metabolic risk factors and kidney function
in a rural Chinese population. We tested whether the
cardiovascular metabolic risk factors were associated
with the estimated glomerular filtration rate (eGFR) and
whether MetS is also associated with an eGFR decrease.
Methods
Study population
The study subjects were from the China Stroke Primary
Prevention Trial (CSPPT, clinical trial number
NCT00794885). The data were collected from residents
of rural areas in Lianyungang City of Jiangsu Province
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and Anqing City of Anhui Province, China. The inclu-
sion criterion was an age of 35–90 years. The exclusion
criteria included a reported history of myocardial infarc-
tion, stroke, heart failure, cancer, or serious mental dis-
orders; unwillingness to participate; and difficulty
completing the survey. The study conformed to the
Declaration of Helsinki and was approved by the ethics
committee of the Institute of Biomedicine, Anhui
Medical University, Hefei, China.
A stratified random cross-sectional survey was
performed using the cluster sampling method. In total,
2426 people aged from 39 to 88 (63 ± 7) years were
screened. All study subjects signed informed consent
forms. The results were used for public data analysis and
the purposes of this study.
Data collection
All study subjects received physical examinations. A
questionnaire was used to collect lifestyle information
and disease history. The smoking conditions were classi-
fied as current, previous, and non-smoking. The body
weight and height were measured in the morning with
the participants wearing light clothing and no shoes.
The BMI was calculated using the equation BMI = body
weight (kg) divided by the square of the body weight
(kg/m2). eGFR was calculated using the Modified Diet in
Renal Disease (MDRD) equation. The blood pressure of
the study subjects was measured using an Omron auto-
matic digital blood pressure monitor (Omron HEM705IT
device; OmronHealth Care) according to the American
Heart Association protocol. The study subjects rested for
at least 5 min and assumed a supine position. The right
arm was placed at the same level as the heart. The meas-
urement was performed 3 times at 2-min intervals. The
mean value was calculated.
Each study subject fasted for 12–16 h prior to the
collection of a venous blood sample. Serum or plasma
samples were separated 30 min after collection, stored in
a −70 °C freezer, and sent together for measurements.
Blood test
Serum creatinine (Cr), urea nitrogen (UN), uric acid
(Ua), fasting plasma glucose (FPG), total cholesterol
(TC), triglyceride (TG), high-density lipoprotein-
cholesterol (HDL-C), and alanine aminotransferase
(ALT) levels were determined using an automatic
analyzer (Roche). The homocysteine level was deter-
mined using high-performance liquid chromatography
(HPLC). eGFR was calculated using the MDRD
equation.
Statistical analyses
We examined the associations of the cardiometabolic
risk factors with eGFR using a general linear model.
Standardized regression coefficients for eGFR on meta-
bolic risk factors were obtained from a standardized lin-
ear regression model where we treated eGFR as the
dependent variable and cardiometabolic risk factors as
independent variables. We further tested the associations
between MetS and eGFR using general linear models
after adjustment for potential confounders (age, gender).
All reported P values are nominal and two sided. Statis-
tical analyses were performed in SAS 9.3 (SAS Institute,
Cary, NC, USA).
Results
Basic characteristics of the study population
The study included 2426 subjects, including 934 men
and 1492 women. The age, waist circumference, BMI,
FPG, HDL-C, TC, TG, Cr, serum albumin, UN, and
blood pressure (including systolic pressure and diastolic
pressure) were assessed for data analysis. The general
information is provided in Table 1.
Association of cardiovascular metabolic risk factors with
eGFR
CKD (chronic kidney disease) is defined as eGFR < 60 ml/
min per 1.73 m2 (MDRD). The 2426 study subjects were
grouped accordingly as eGFR ≥ 90 ml/min/1.73 m2 (1611
cases), eGFR = 60–89 ml/min/1.73 m2 (773 cases), and
eGFR < 60 ml/min/1.73 m2 (42 cases) prior to the correl-
ation analysis. The results showed that the risk factors
age, waist circumference, Cr, HDL-C, TC, TG, systolic
pressure, and diastolic pressure of the population with
lower values of eGFR were significantly higher than those
of the population with higher values of eGFR (P for trend:
<0.05). In contrast, eGFR and body weight showed a
negative correlation (P for trend: 0.0026) (Table 2).
Table 1 Characteristics of the study sample (mean ± S.D.)
Characteristics Men Women
Number 934 1492
Age (years) 63.95 ± 7.20 61.63 ± 7.47
Waist (cm) 77.45 ± 10.13 79.38 ± 10.34
Body mass index (kg/m) 21.94 ± 3.24 23.35 ± 3.63
Fasting plasma glucose (mg/dl) 6.18 ± 1.99 6.14 ± 1.96
HDL cholesterol (mg/dl) 1.51 ± 0.39 1.47 ± 0.34
Total cholesterol (mg/dl) 4.92 ± 0.92 5.29 ± 1.06
Triglycerides (mg/dl) 1.37 ± 0.89 1.81 ± 1.25
Systolic blood pressure (mmHg) 125.05 ± 19.15 126.05 ± 18.97
Diastolic blood pressure (mmHg) 79.70 ± 10.69 78.77 ± 9.72
Creatinine (μmol/L) 87.66 ± 18.05 73.00 ± 15.36
Glomerular filtration rate 103.82 ± 21.12 96.19 ± 20.44
Albumin (g/L) 47.84 ± 3.55 48.26 ± 3.53
Blood urea nitrogen (mmol/L) 6.36 ± 1.84 5.84 ± 1.68
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Standardized linear regression analysis was performed
on the 2426 study subjects. eGFR was used as a dependent
variable, and age, body weight, waist circumference, HDL-
C, TC, TG, systolic pressure, and diastolic pressure were
individually introduced into the model. The results
showed that the eGFR gradually decreased as the meta-
bolic risk factors increased. The decrease in the standard
deviations of eGFR per standard deviation of the increase
in the metabolic risk factors ranged from 0.05 (waist) to
0.25 (age) (Fig. 1).
Association between MetS and eGFR
MetS was defined as the presence of at least 3 of 5
risk factors (waist circumference, TG, HDL-C, blood
pressure, and fasting plasma glucose). Specifically, the
risk factors were enlarged waist circumference accord-
ing to population-specific and country-specific cri-
teria; TG ≥ 150 mg/dl; HDL-c < 40 mg/dl in men and
<50 mg/dl in women; systolic blood pressure ≥
130 mm Hg or diastolic blood pressure ≥ 85 mm Hg;
and FPG > 100 mg/dl. Patients taking medication to
manage hypertriglyceridemia, low HDL-c, hyperten-
sion or hyperglycemia were also included [7]. The re-
sults showed that the eGFR gradually and linearly
decreased as the number of MetS risk factors in-
creased (Fig. 2).
Discussion
We mainly found that cardiovascular metabolic risk
factors correlated with the eGFR. The eGFR gradually
decreased as the metabolic syndrome risk factors
increased in the rural Chinese population.
A systemic analysis of the European population
showed that increased blood pressure and TG and de-
creased LDL-C, obesity, and glucose metabolic disorders
were significantly associated with CKD development
(eGFR < 60 ml/min per 1.73 m2) and eGFR reduction.
Additionally, the strength of this correlation increased as
the number of the above factors increased [8]. Our study
results in the Chinese population were consistent with
Table 2 Metabolic risk factors according to eGFR
Characteristic eGFR≥ 90 (n = 1611) eGFR 89–60 (n = 773) eGFR < 60 (n = 42) P for trend
Age (years) 61.54 ± 7.21 64.27 ± 7.52 67.88 ± 7.22 <.0001
Weight (kg) 56.56 ± 9.97 55.41 ± 9.92 54.74 ± 11.44 0.0026
Waist (cm) 78.41 ± 10.20 79.08 ± 10.47 79.19 ± 10.87 0.0191
Fasting plasma glucose (mg/dl) 6.08 ± 1.93 6.22 ± 1.86 8.00 ± 3.85 0.0609
Creatinine (μmol/L) 72.05 ± 11.80 88.86 ± 12.31 143.58 ± 51.86 <.0001
Glomerular filtration rate 109.66 ± 16.82 79.85 ± 7.51 49.61 ± 10.64 <.0001
HDL cholesterol (mg/dl) 1.47 ± 0.34 1.51 ± 0.37 1.59 ± 0.69 0.0021
Total cholesterol (mg/dl) 5.03 ± 0.94 5.33 ± 1.10 6.03 ± 1.63 <.0001
Triglycerides (mg/dl) 1.58 ± 1.12 1.73 ± 1.18 2.21 ± 1.02 0.0021
Systolic blood pressure (mmHg) 124.48 ± 18.42 127.73 ± 19.88 133.05 ± 22.06 0.0144
Diastolic blood pressure (mmHg) 78.71 ± 9.97 79.92 ± 10.34 80.65 ± 10.83 <.0001
Fig. 1 Standardized regression coefficients for eGFR vs metabolic risk factors. The decrease in standard deviations of eGFR per standard deviation
increase in the metabolic risk factors ranged from 0.05 (waist) to 0.25 (age)
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previous studies showing a negative correlation between
eGFR and cardiovascular metabolic risk factors, such as
hypertension, hypercholesterolemia, and hypertriglyc-
eridemia, as well as reduced HDL-C hyperlipidemia and
obesity. Studies on a European population showed that
hypertriglyceridemia and a low HDL-C level were both
risk factors for eGFR reduction in the non-kidney dis-
ease population and for CKD progression in kidney dis-
ease patients [9–11]. In the healthy population, age is
the most important factor that causes a reduction in kid-
ney function; an increase in blood pressure and in char-
acteristics of metabolic disorders, such as high blood
glucose and blood lipid lipids, are also correlated with
age [12–14]. Our study found that age was associated
with a reduction in eGFR. In addition, hypertension is
one risk factor for mortality worldwide [15]. The studies
by Kurella et al. and Rashidi et al. both showed that in-
creased blood pressure plays an important role in the in-
crease in the CKD incidence rate [16, 17], which was
consistent with our study results. Our results showed
that an increase in diastolic pressure had greater effects
on the reduction in eGFR than an increase in systolic
pressure.
Kurella et al. performed a 9-year prospective cohort
study on adults without diabetes mellitus. In 2005, MetS
was reported to be an independent risk factor for CKD
development; the relative risk for CKD was higher
among people with more abnormal MetS-associated fac-
tors. This study suggested that MetS is the major cause
of CKD in the US population, independent of diabetes
and hypertension [16]. One prospective cohort study on
MetS in non-diabetic patients showed that MetS
increased the risk for CKD [18]. Furthermore, a pro-
spective cohort study on type 2 diabetes mellitus
patients showed that MetS was associated with the CKD
incidence, with central obesity, hypertriglyceridemia, and
hypertension serving as independent predictive factors
for CKD [16, 19].
A systematic review indicated that obesity was as-
sociated with CKD incidence and could increase the
risk for CKD [8, 20, 21]. Additionally, a reduction in
body weight could increase the eGFR in overweight
males (BMI ≥ 25 kg/m2). Therefore, a reduction in
body weight has kidney-protective effects in obese
patients [22]. Studies by Kurella et al. and Chen et
al. emphasized that obesity, especially the central
obesity indicator waist circumference, was an inde-
pendent risk factor for CKD [16, 23], which was
consistent with our study results. The major path-
ology of obesity-related glomerulopathy (ORG) is
glomerular hypertrophy, which can develop into sec-
ondary focal segmental glomerulosclerosis [24, 25].
The underlying mechanism is that adipose tissue
synthesizes and secretes angiotensinogen, subse-
quently causing glomerular hypertrophy. Further-
more, insulin resistance increases type I and type IV
collagen and fibronectin synthesis and induces seg-
mental sclerosis, sclerosis of the glomeruli, and the
development of obesity-related focal segmental glo-
merulosclerosis [26, 27].
Several limitations should be considered. First, the
study population was selected from a rural area. Further-
more, the prevalence of cardiovascular events differs by
region, ethnic group, and dietary habits in China [28, 29].
Therefore, the results from the present study cannot be
generalized to the whole population. Second, the present
study was cross-sectional; therefore, we cannot causally
connect cardiovascular risk factors and eGFR. Third,
although previous studies showed that abnormal blood
glucose metabolism was associated with cardiovascular
risk factors and a reduction in eGFR, our study did not
show a correlation between an eGFR reduction and blood
Fig. 2 Metabolic syndrome and eGFR
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glucose, possibly due to the limited number of people with
abnormal blood glucose in the selected population.
Conclusions
Our study suggests that cardiovascular metabolic risk
factors correlate with eGFR. Metabolic syndrome was
associated with a reduction in kidney function and CKD.
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